Author: Krumm, Zachary A.; Lloyd, Grace M.; Francis, Connor P.; Nasif, Lith H.; Mitchell, Duane A.; Golde, Todd E.; Giasson, Benoit I.; Xia, Yuxing
Title: Precision therapeutic targets for COVID-19 Cord-id: u40ytbyl Document date: 2021_3_29
ID: u40ytbyl
Snippet: Beginning in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as a novel pathogen that causes coronavirus disease 2019 (COVID-19). SARS-CoV-2 has infected more than 111 million people worldwide and caused over 2.47 million deaths. Individuals infected with SARS-CoV-2 show symptoms of fever, cough, dyspnea, and fatigue with severe cases that can develop into pneumonia, myocarditis, acute respiratory distress syndrome, hypercoagulability, and even multi-organ failure
Document: Beginning in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as a novel pathogen that causes coronavirus disease 2019 (COVID-19). SARS-CoV-2 has infected more than 111 million people worldwide and caused over 2.47 million deaths. Individuals infected with SARS-CoV-2 show symptoms of fever, cough, dyspnea, and fatigue with severe cases that can develop into pneumonia, myocarditis, acute respiratory distress syndrome, hypercoagulability, and even multi-organ failure. Current clinical management consists largely of supportive care as commonly administered treatments, including convalescent plasma, remdesivir, and high-dose glucocorticoids. These have demonstrated modest benefits in a small subset of hospitalized patients, with only dexamethasone showing demonstrable efficacy in reducing mortality and length of hospitalization. At this time, no SARS-CoV-2-specific antiviral drugs are available, although several vaccines have been approved for use in recent months. In this review, we will evaluate the efficacy of preclinical and clinical drugs that precisely target three different, essential steps of the SARS-CoV-2 replication cycle: the spike protein during entry, main protease (M(Pro)) during proteolytic activation, and RNA-dependent RNA polymerase (RdRp) during transcription. We will assess the advantages and limitations of drugs that precisely target evolutionarily well-conserved domains, which are less likely to mutate, and therefore less likely to escape the effects of these drugs. We propose that a multi-drug cocktail targeting precise proteins, critical to the viral replication cycle, such as spike protein, M(Pro), and RdRp, will be the most effective strategy of inhibiting SARS-CoV-2 replication and limiting its spread in the general population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-021-01526-y.
Search related documents:
Co phrase search for related documents- abnormal blood clotting and acute therapy: 1
- absence presence and ace inhibitor: 1
- absence presence and action mechanism: 1, 2, 3, 4, 5, 6
- absence presence and active site: 1, 2, 3, 4, 5, 6, 7, 8
- absence presence and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- absence presence and acute phase response: 1
- absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- absence presence and acute therapy: 1, 2
- absence presence and adaptive immune response: 1, 2
- absence presence and additional file: 1, 2, 3, 4, 5, 6, 7
- absence presence and additional population: 1
- absence presence and long range: 1
- absence presence and long term immunity: 1, 2, 3, 4
- absence presence and lopinavir ritonavir: 1, 2
- absence presence and low specificity: 1, 2
- absence presence and low toxicity: 1, 2
- absence presence and lung epithelial: 1, 2, 3, 4
- absence presence and lung epithelial cell: 1
- absence presence and lung function: 1, 2
Co phrase search for related documents, hyperlinks ordered by date